Screener
Eligibility screening
Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
29 US sites in CA, CO, CT, FL +13
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.